戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 t it is mediated by the autocrine release of endogenous cannabinoids.
2 t cellular and organismal levels compared to endogenous cannabinoids.
3 ed increased responses to elevated levels of endogenous cannabinoids.
4 and immunological actions of Delta(9)THC and endogenous cannabinoids.
5 ating the cognitive actions of marijuana and endogenous cannabinoids.
6 smission that involves the production of the endogenous cannabinoid 2-arachidonoyl glycerol (2-AG).
7 rrelation between enhanced production of the endogenous cannabinoid 2-arachidonoylglycerol (2-AG) and
8 ility to demonstrate a critical role for the endogenous cannabinoid 2-arachidonoylglycerol (2-AG) in
9                                          The endogenous cannabinoid 2-arachidonoylglycerol (2-AG) is
10 embrane serine hydrolase that hydrolyzes the endogenous cannabinoid 2-arachidonoylglycerol (2-AG) to
11 iatal levels of AEA, but not the other major endogenous cannabinoid 2-arachidonoylglycerol (2-AG), du
12 e demonstrate that rat platelets contain the endogenous cannabinoid 2-arachidonyl glyceride (2-AG), a
13 a), the principal biosynthetic enzyme of the endogenous cannabinoid 2-arachidonylglycerol (2-AG) on n
14                                              Endogenous cannabinoids acting at CB(1) receptors stimul
15 rstanding how exogenous (e.g., cannabis) and endogenous cannabinoids affect behavior.
16 ting fatty acid amides including anandamide (endogenous cannabinoid agonist) and oleamide (sleep-indu
17 nsible for the degradation of anandamide, an endogenous cannabinoid agonist, and oleamide, a sleep-in
18                                              Endogenous cannabinoids also promote food-seeking behavi
19 ylglycerol (2-AG) are the most characterized endogenous cannabinoids (also known as endocannabinoids)
20                                          The endogenous cannabinoid anandamide (AEA) is a lipid media
21                                          The endogenous cannabinoid anandamide (N-arachidonoylethanol
22 omodulatory fatty acid amides, including the endogenous cannabinoid anandamide and the sleep-inducing
23 omodulatory fatty acid amides, including the endogenous cannabinoid anandamide and the sleep-inducing
24 omodulatory fatty acid amides, including the endogenous cannabinoid anandamide and the sleep-inducing
25 yme that degrades lipid amides including the endogenous cannabinoid anandamide and the sleep-inducing
26 lass of lipid transmitters that includes the endogenous cannabinoid anandamide and the sleep-inducing
27 ogenous signaling lipids, which includes the endogenous cannabinoid anandamide and the sleep-inducing
28 or the uptake and cellular processing of the endogenous cannabinoid anandamide are not well understoo
29 cilitated transport process that removes the endogenous cannabinoid anandamide from extracellular spa
30                                          The endogenous cannabinoid anandamide has recently been iden
31  permitted measurement of the release of the endogenous cannabinoid anandamide in the periaqueductal
32                                          The endogenous cannabinoid anandamide is removed from the sy
33  to the synthetic cannabinoid HU-210 and the endogenous cannabinoid anandamide led to significant ind
34             These findings indicate that the endogenous cannabinoid anandamide plays an important rol
35                        We also observed that endogenous cannabinoid anandamide was able to reduce hep
36 cluding known signaling molecules (e.g., the endogenous cannabinoid anandamide) and a novel family of
37         Although structurally related to the endogenous cannabinoid anandamide, OEA does not bind to
38 nzyme responsible for the degradation of the endogenous cannabinoid anandamide.
39 tions of polyunsaturated NAEs, including the endogenous cannabinoid anandamide.
40  class of signaling lipids that includes the endogenous cannabinoid anandamide.
41 binoid receptors, CB1 and CB2, and the major endogenous cannabinoids (anandamide and 2-arachidonoyl g
42 id effect was mimicked by application of the endogenous cannabinoid, anandamide and blocked by VR1 an
43              Methanandamide (an analog of an endogenous cannabinoid, anandamide) also reduced cell su
44                                 The two main endogenous cannabinoids, anandamide and 2-arachidonoyl g
45 achidonoylglycerol (2-AG), the most abundant endogenous cannabinoid and a full agonist for cannabinoi
46 s in the CNS is indicated by the presence of endogenous cannabinoids and cannabinoid receptors.
47 ing cannabinoid receptors using exogenous or endogenous cannabinoids and use of FAAH inhibitors may c
48 platelets and macrophages generate different endogenous cannabinoids, and that both 2-AG and anandami
49 is thought that the physiological actions of endogenous cannabinoid arachidonylethanolamide (AEA), as
50 porting a possible physiological role for an endogenous cannabinoid, arachidonylethanolamide (AEA, an
51                             The best-studied endogenous cannabinoids are 2-arachidonoyl glycerol and
52                                    Moreover, endogenous cannabinoids are physiological immune regulat
53 endocrine output, presaging the emergence of endogenous cannabinoids as important signalling molecule
54 stem consisting of cannabinoid receptors and endogenous cannabinoids as well as the enzymatic machine
55                                 However, the endogenous cannabinoids, as well as Delta(9)-tetrahydroc
56 to develop drugs that amplify the effects of endogenous cannabinoids by preventing their inactivation
57                           Both exogenous and endogenous cannabinoids can allosterically modulate glyc
58  In contrast to classical neurotransmitters, endogenous cannabinoids can function as retrograde synap
59                                              Endogenous cannabinoids can thereby rapidly enhance inhi
60 regnancy has the potential to interfere with endogenous cannabinoid (CB) regulation of fetal nervous
61 en reported to be activated by exogenous and endogenous cannabinoid compounds but surprisingly also b
62              delta9-Tetrahydrocannabinol and endogenous cannabinoids (e.g., anandamide) initiate thei
63              Pharmacological augmentation of endogenous cannabinoid (eCB) signaling has been suggeste
64  correlates that accompany the disruption of endogenous cannabinoid (eCB) signaling in a food-motivat
65                              Augmentation of endogenous cannabinoid (eCB) signaling represents an eme
66 biobehavioral processes heavily modulated by endogenous cannabinoid (eCB) signaling.
67          Anxiety is further modulated by the endogenous cannabinoid (eCB) system that attenuates the
68 presents a primary degradation enzyme of the endogenous cannabinoid (eCB), 2-arachidonoyglycerol (2-A
69 t GABAergic inhibition in DGCs is subject to endogenous cannabinoid (eCB)-mediated retrograde regulat
70         Further, pharmacologically enhancing endogenous cannabinoids (eCB) with JZL184 prevents absti
71                           The oxygenation of endogenous cannabinoids (eCBs) 2-arachidonoyl glycerol (
72                            Melanocortins and endogenous cannabinoids (eCBs) have been implicated in t
73 e current study to investigate if intraislet endogenous cannabinoids (ECs) regulate beta-cell prolife
74             The cellular inactivation of the endogenous cannabinoid (endocannabinoid) anandamide (AEA
75  acid amide hydrolase (FAAH) inactivates the endogenous cannabinoid (endocannabinoid) anandamide and
76                                              Endogenous cannabinoids (endocannabinoids) are endogenou
77                                          The endogenous cannabinoids (endocannabinoids) are lipid mol
78                                              Endogenous cannabinoids (endocannabinoids) are small mol
79             Retrograde synaptic signaling by endogenous cannabinoids (endocannabinoids) is a recently
80 ly inhibited by cannabinoids in the NAc, and endogenous cannabinoids (endocannabinoids) play a critic
81 m potentiation (LTP) in the hippocampus, yet endogenous cannabinoids (endocannabinoids) transiently s
82     The ECS comprises cannabinoid receptors, endogenous cannabinoids (endocannabinoids), and the enzy
83 omprising CB1 and CB2 cannabinoid receptors, endogenous cannabinoids (endocannabinoids), and the enzy
84                                              Endogenous cannabinoids (endocannabinoids, eCBs) are ubi
85 t in vitro studies have described a role for endogenous cannabinoids ("endocannabinoids") as transsyn
86                    The signaling capacity of endogenous cannabinoids ("endocannabinoids") is tightly
87 nnabis, and mediate physiological effects of endogenous cannabinoids ('endocannabinoids').
88      Thus, 2-arachidonylglycerol, a putative endogenous cannabinoid ester, also may serve as a substr
89  by which cannabidiol or other exogenous and endogenous cannabinoids exert their therapeutic effects.
90                         Exogenous as well as endogenous cannabinoids have been shown to target voltag
91 (2-AG) and depolarization-induced release of endogenous cannabinoids have minimal effect on mIPSC fre
92  GABA release was tonically suppressed by an endogenous cannabinoid in vitro.
93 findings suggest that Purkinje cells release endogenous cannabinoids in response to elevated calcium,
94 these findings suggest a widespread role for endogenous cannabinoids in retrograde synaptic inhibitio
95     Recent research has suggested a role for endogenous cannabinoids in the descending inhibition of
96 ese experiments argue for the involvement of endogenous cannabinoids in time estimation.
97 l cells were treated with both synthetic and endogenous cannabinoids in vitro, and biochemical coupli
98                                          The endogenous cannabinoids, including the closely related l
99 se findings strongly suggest that release of endogenous cannabinoids is involved in brain reward proc
100 nt, retrograde inhibition of GABA release by endogenous cannabinoids is persistently enhanced in the
101                                          The endogenous cannabinoid ligand anandamide is biosynthesiz
102                   2-AG is the most prevalent endogenous cannabinoid ligand in the brain, and electrop
103   Our results indicate that 2-AG is a second endogenous cannabinoid ligand in the central nervous sys
104                             Anandamide is an endogenous cannabinoid ligand, and its levels are spatio
105                               Anandamide, an endogenous cannabinoid ligand, binds to CB1 cannabinoid
106                                              Endogenous cannabinoid ligands (endocannabinoids) produc
107  of anandamide (arachidonylethanolamide), an endogenous cannabinoid lipid, are terminated by a two-st
108    The effect of SR 141716A suggests that an endogenous cannabinoid may mediate striato-nigral transm
109 vel of the thalamus and that one function of endogenous cannabinoids may be to modulate pain sensitiv
110 y CB1 cannabinoid receptors, indicating that endogenous cannabinoids may contribute to the control of
111 d suppression of excitation (DSE), a form of endogenous cannabinoid-mediated retrograde synaptic plas
112                                           If endogenous cannabinoids modulate basal nociceptive thres
113 141716A was used to test the hypothesis that endogenous cannabinoids modulate tonic pain sensitivity.
114 plays a central role in the lifecycle of the endogenous cannabinoid N-arachidonoylethanolamine (anand
115 deducing the bioactive conformation of these endogenous cannabinoids, not only at the CB receptors bu
116 rform a comparative study with synthetic and endogenous cannabinoids on their effects on synaptic con
117                                              Endogenous cannabinoids play a central role in the modul
118    These findings suggest that exogenous and endogenous cannabinoids potentiate GlyRs via a hydrogen
119 oactive ingredients in marijuana, as well as endogenous cannabinoids produced in the brain.
120 suggests an additional mode of regulation of endogenous cannabinoid receptor activity.
121                                          The endogenous cannabinoid receptor agonist anandamide is pr
122  and this molecule is well established as an endogenous cannabinoid receptor agonist in the brain.
123               In Caenorhabditis elegans, the endogenous cannabinoid receptor agonist, 2-arachidonoylg
124      The present study demonstrates that the endogenous cannabinoid receptor agonists 2-arachidonoylg
125                     Several analogues of the endogenous cannabinoid receptor ligand arachidonylethano
126            These amides were compared to the endogenous cannabinoid receptor ligand arachidonylethano
127 ated oxygenases capable of metabolizing this endogenous cannabinoid receptor ligand.
128  of arachidonylethanolamide (anandamide), an endogenous cannabinoid receptor ligand.
129 cologic effects, and has been proposed as an endogenous cannabinoid receptor ligand.
130                                     Although endogenous cannabinoid receptors (CB(1)Rs) are abundantl
131 ction of THC is specific (i.e., mediated via endogenous cannabinoid receptors) or non-specific, refle
132 lation of appetite hormones mediated through endogenous cannabinoid receptors, independent of glucose
133                                  We measured endogenous cannabinoid release in dorsal striatum of fre
134 ting that retrograde synaptic suppression by endogenous cannabinoids represents a widespread signalin
135 e (FAAH), which leads to increased levels of endogenous cannabinoids, resulted in decreased liver inj
136 rotransmission, raising the possibility that endogenous cannabinoids serve naturally to modulate pain
137                  These findings suggest that endogenous cannabinoids serve naturally to modulate the
138                               Anandamide, an endogenous cannabinoid signaling molecule, in a concentr
139 e consistent with a neuroprotective role for endogenous cannabinoid signaling pathways and with a pot
140                                              Endogenous cannabinoid signaling pathways have been impl
141                 These findings indicate that endogenous cannabinoid signaling pathways protect mice f
142 olar cells suggest a substantive role for an endogenous cannabinoid signaling system in retinal physi
143                 If the effects occur via the endogenous cannabinoid signaling system, then this may r
144 iterature on the effects of cannabinoids and endogenous cannabinoid signaling systems in the regulati
145 nisms of action, including a facilitation of endogenous cannabinoid signaling via one of its metaboli
146 rons, a well-characterized neuronal model of endogenous cannabinoid signaling, and in CHO-K1 cells.
147 e a (DAGLa), a major biosynthetic enzyme for endogenous cannabinoid signaling, has emerged as a risk
148  with potentially physiologically restricted endogenous cannabinoid signaling, may be more vulnerable
149  sites offer novel targets for modulation of endogenous cannabinoid signalling.
150        Here, we test the hypothesis that the endogenous cannabinoid sn-2-arachidonoylglycerol (2-AG)
151 ication and quantification of anandamide, an endogenous cannabinoid substance, and other fatty acid e
152  anandamide (N-arachidonoylethanolamine), an endogenous cannabinoid substance, may be produced throug
153                               Anandamide, an endogenous cannabinoid substance, suppresses the potassi
154 view of the possible role of these lipids as endogenous cannabinoid substances.
155  the release of anandamide, but not of other endogenous cannabinoids such as 2-arachidonylglycerol.
156 ls, but there is only indirect evidence that endogenous cannabinoids such as anandamide participate i
157     The IPSCs are regulated by exogenous and endogenous cannabinoids, suggesting that they arise from
158  GAD(67)-mediated GABA synthesis by reducing endogenous cannabinoid suppression of GABA release.
159 link between functional abnormalities in the endogenous cannabinoid system and drug abuse and depende
160                                          The endogenous cannabinoid system appears to serve vascular,
161                                          The endogenous cannabinoid system has been implicated in dru
162    Although emerging evidence implicates the endogenous cannabinoid system in aspects of opioid and e
163                        Investigations of the endogenous cannabinoid system in the prefrontal cortex o
164                  To evaluate the role of the endogenous cannabinoid system in the regulation of basal
165 results suggest that neuroadaptations in the endogenous cannabinoid system may be part of the neuropl
166 ing SR141716A and SR144528 indicate that the endogenous cannabinoid system may be tonically active in
167              These results indicate that the endogenous cannabinoid system may represent a potential
168                                 Although the endogenous cannabinoid system modulates a variety of phy
169 rinatal and adolescent periods, in which the endogenous cannabinoid system plays a fundamental role i
170 lopmental signals.SIGNIFICANCE STATEMENT The endogenous cannabinoid system plays diverse roles in bra
171 of GMV effects mapped onto biomarkers of the endogenous cannabinoid system providing insight into pos
172 butable to the disruption by cannabis of the endogenous cannabinoid system's spatiotemporal regulatio
173 uding disturbances in the development of the endogenous cannabinoid system, are discussed.
174 wal has been established via discovery of an endogenous cannabinoid system, identification of cannabi
175  suggesting a role for this oxygenase in the endogenous cannabinoid system.
176 re mediated by receptors that are part of an endogenous cannabinoid system.
177                               Given that the endogenous cannabinoid (that is, endocannabinoid) system
178 n, stress elicits the rapid formation of two endogenous cannabinoids, the lipids 2-arachidonoylglycer
179 mponent found in marijuana or anandamide, an endogenous cannabinoid, to DC cultures induced apoptosis
180  investigation uncovered a specific role for endogenous cannabinoid tone in timing behavior, as eleva
181  of anandamide signaling in vivo, setting an endogenous cannabinoid tone that modulates pain percepti
182                            We also show that endogenous cannabinoids tonically regulate pain threshol
183 udies have demonstrated that the majority of endogenous cannabinoid type 1 (CB(1)) receptors do not r
184               Using GC/MS to detect possible endogenous cannabinoids, we found 3 nmol of 2-arachidony

 
Page Top